In These Three Countries, Getting Sick Does Not Mean Going Broke

In the United States, healthcare-related financial distress is a structural constant for a significant portion of the population. For many households, a successful clinical outcome for a major illness is frequently followed by the arrival of medical bills that exceed total liquid assets. According to data from World Population Review, medical expenses or illness-related loss of income are cited as contributing factors in approximately 66.5 percent of all personal bankruptcies in the U.S.

This translates to several hundred thousand filings annually where healthcare costs serve as a primary catalyst for financial collapse. Data from Debt.org indicates that total personal bankruptcy filings have remained a persistent feature of the economic landscape, with hundreds of thousands of Americans seeking court protection each year. As of 2024, the total medical debt in the U.S. is estimated at $220 billion, affecting roughly 100 million people, or nearly one in three adults.

The financial pressure on American households is distinct when compared to other developed economies. While U.S. healthcare spending reached an estimated $4.8 trillion in 2023—representing between 17.3 and 18 percent of the national GDP—outcomes regarding financial protection vary wildly from peer nations. In systems like those found in Taiwan, France, and Australia, the risk of insolvency following a medical diagnosis is mitigated by specific fiscal architectures designed to absorb catastrophic costs.

Administrative Leaness in Taiwan

While U.S. insurers grapple with double-digit overhead, Taiwan’s single-payer system operates on a margin significantly narrower than those found in the American private sector. According to the Taiwan National Health Insurance Administration’s 2024-2025 Annual Report, administrative costs are maintained at approximately 0.9 percent of total expenditures. In contrast, U.S. private insurers typically report administrative overhead ranging between 12 and 18 percent.

Source: Taiwan NHIA / CMS

The Taiwan National Health Insurance (NHI) system provides universal coverage with a premium structure that, as of 2024, is set at 5.17 percent of income. The system is designed to prevent large households from facing disproportionate costs by capping the number of dependents for which a primary earner must pay premiums. This centralized approach allows the NHI to maintain a stable reserve fund, which reached $7 billion at the end of 2023, providing a buffer against the rising costs associated with an aging population.

Taiwan is currently transitioning into a “super-aged society,” a demographic shift that saw its NHI global budget cross the NT$1 trillion threshold. Despite these pressures, the system’s ability to negotiate prices as a single payer has kept the out-of-pocket burden for citizens low. Patients in Taiwan can often access specialist care with co-payments of less than $20, a figure that remains stable due to the government’s aggressive management of the global budget.

France: Eliminating the Burden of Co-payments

The French model focuses on the aggressive reduction of “hidden” costs that often lead to debt even in universal systems. For years, dental, vision, and hearing services were notable gaps in coverage that required significant patient contributions. The “100% Santé” (100% Health) initiative was implemented to address this by requiring insurers and providers to offer a specific tier of medical devices—such as glasses, dentures, and hearing aids—with no out-of-pocket costs for the patient.

Data from the DREES 2024 report (Edition 2025) shows that France maintains one of the lowest out-of-pocket spending rates among OECD nations. French patients pay only about 9 percent of total health expenditure directly. This is supported by a Social Security system that covered approximately 80 percent of total healthcare spending in 2024, accounting for 11.4 percent of France’s GDP.

To manage the system’s deficit, recent fiscal adjustments have involved modest increases in fixed co-payments for certain medical acts and prescriptions. However, the French government maintains a protective ceiling, capping annual co-payments at €100 per person. This ensures that patients with chronic conditions or those requiring high-frequency care are not exposed to open-ended financial liability, a sharp contrast to the U.S. model where high-deductible plans can require thousands of dollars in spending before insurance coverage fully engages.

Australia’s Tiered Safety Net

Australia utilizes a hybrid system that combines a public health floor with a private insurance ceiling. The primary mechanism for preventing medical-related poverty is the Medicare Safety Net (MSN). This system is designed to trigger automatically once a patient reaches a certain threshold of out-of-pocket spending for out-of-hospital services.

For 2024, the MSN thresholds are approximately $560 for concessional patients (including pensioners and low-income earners) and $2,544 for all other patients. Once these limits are reached, the government covers 80 percent of subsequent out-of-pocket costs for the remainder of the calendar year. A similar protection exists for prescription drugs through the Pharmaceutical Benefits Scheme (PBS), where the safety net threshold for concessional cardholders is less than $300 annually.

Despite these protections, some segments of the Australian population report increasing financial strain related to “gap fees.” Analysis of Medicare data indicates that specialist fees often exceed the government’s scheduled rebates, leaving patients to cover the difference. While approximately 10 percent of Australians report skipping or postponing care due to cost, this remains significantly lower than the 36 percent of U.S. adults who reported similar barriers in 2023, according to KFF data.

The Role of Market Dynamics and R&D

The divergence in healthcare costs between the U.S. and the rest of the world is often attributed to the funding source. Across the OECD, government or compulsory schemes fund approximately 75 percent of healthcare. In the United States, that figure is only about 50 percent, placing a larger share of the financial burden on individuals and private employers.

However, the higher costs in the U.S. market serve a specific role in the global medical ecosystem. The U.S. is the primary source of revenue for the global pharmaceutical and medical device industries, providing the high-margin environment necessary to fund research and development (R&D). The high domestic prices paid by American consumers and insurers effectively subsidize the development of next-generation therapeutics that are eventually adopted by the more cost-constrained systems in Taiwan, France, and Australia.

This creates a complex global dynamic: while U.S. patients face a higher risk of bankruptcy, the capital generated by the U.S. healthcare market drives much of the innovation that improves global health outcomes. For the American worker, this results in a system that offers the world’s most advanced treatments but often lacks the fiscal architecture to ensure those treatments do not lead to financial ruin.

As the U.S. continues to see a high volume of bankruptcy filings linked to medical debt, the comparison with international models highlights a choice between different types of efficiency. Systems in Europe and Asia prioritize the distribution of the financial burden to ensure stability for the individual, while the U.S. system prioritizes a market-driven model that incentivizes innovation but leaves the individual household to manage the risk of catastrophic costs. Until the U.S. implements more robust safety nets or reduces administrative overhead, medical debt will likely remain a leading cause of insolvency for American families.